Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042210 | 0.74 | CES2 (0.46) | SMN1; SMN2CES2CES1HDAC8HDAC6 | |
| SCHEMBL17430884 | 0.74 | CES2 (0.46) | SMN1; SMN2CES2CES1HDAC8HDAC6 | |
| SCHEMBL25240690 | 0.73 | CES2 (0.41) | SMN1; SMN2CES2CES1HDAC8HDAC6 | |
| SCHEMBL14336987 | 0.73 | NPSR1 (0.36) | SMN1; SMN2CES2CES1HDAC8HDAC6 | |
| SCHEMBL14336967 | 0.73 | NPSR1 (0.49) | SMN1; SMN2EPHX1NPSR1POLBALDH1A1 | |
| SCHEMBL25706 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2NPSR1TSHRALDH1A1 | |
| SCHEMBL3001721 | 0.71 | NPSR1 (0.33) | SMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL5045982 | 0.69 | CES2 (0.41) | SMN1; SMN2CES2CES1HDAC8HDAC6 | |
| SCHEMBL8644101 | 0.69 | CES2 (0.41) | SMN1; SMN2CES2CES1HDAC8HDAC6 | |
| SCHEMBL8650880 | 0.69 | CES2 (0.41) | SMN1; SMN2CES2CES1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048604-A1 | Ligands for Aldoketoreductases | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2010-02-25 | — | — | US | disclosed |
| WO-2006023821-A2 | LIGANDS FOR ALDOKETOREDUCTASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-0646570-B1 | PROCESS FOR PRODUCING LIGNAN COMPOUND | SHIONOGI & CO (JP) | 1998-06-24 | — | — | EP | disclosed |
| US-5488134-A | Preparation of compounds of lignan series | SHIONOGI & CO., LTD. (JP) | 1996-01-30 | — | — | US | disclosed |
| CN-1109685-A | Process for producing lignan compound | SHIONOGI & CO (JP) | 1995-10-04 | — | — | CN | disclosed |
| EP-0646570-A1 | PROCESS FOR PRODUCING LIGNAN COMPOUND | SHIONOGI & CO., LTD. (JP) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048604-A1 | Ligands for Aldoketoreductases | AKR1C2, AKR1C1, AKR1B1 | SMN1; SMN2 2620/4885CES2 933/4885CES1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.